Revolution Medicines D
RVMD
Revolution Medicines company profile
- CEO
- Mark A. Goldsmith
- Employees
- 883
- Headquarters
- 700 Saginaw Drive, Redwood City, CA 94063, US
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO date
- 13 Feb 2020
- Stock exchange
- NASDAQ
- ISIN
- US76155X1000
Website:revmed.com
About the company
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Employees
Revolution Medicines had about 883 employees at the end of fiscal year 2025 (31 December 2025), by its annual report. That is 65.4% more than a year before.
Employees at each fiscal year end, as the company reports them in its annual report (10-K); revenue and net income per employee are the fiscal year's over that count.
Who owns Revolution Medicines
Institutions such as funds, banks and insurers held 102.4% of Revolution Medicines's shares on 30 June 2026, 738 of them reporting holdings to the SEC; the rest is held by individual investors and other shareholders.
Shares free to trade
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Common questions about Revolution Medicines
Source: Financial Modeling PrepVerified against SEC filings